Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/2000

01-08-2000

Studies on the Cytotoxic, Biochemical and Anti-Carcinogenic Potentials of Ninhydrin on Ehrlich Ascites Carcinoma Cell-Bearing Swiss Albino Mice

Authors: S. Qureshi, O.A. Al-Shabanah, A.M. Al-Bekairi, M.M. Al-Harbi, N.M. Al-Gharably, M. Raza

Published in: Investigational New Drugs | Issue 3/2000

Login to get access
Metadata
Title
Studies on the Cytotoxic, Biochemical and Anti-Carcinogenic Potentials of Ninhydrin on Ehrlich Ascites Carcinoma Cell-Bearing Swiss Albino Mice
Authors
S. Qureshi
O.A. Al-Shabanah
A.M. Al-Bekairi
M.M. Al-Harbi
N.M. Al-Gharably
M. Raza
Publication date
01-08-2000
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 3/2000
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1023/A:1006465504723

Other articles of this Issue 3/2000

Investigational New Drugs 3/2000 Go to the issue

OriginalPaper

A Phase II Trial of Etoposide, Leucovorin, 5-FU, and Interferon Alpha 2b (ELFI) + G-CSF for Patients with Pancreatic Adenocarcinoma: a Southwest Oncology Group Study (SWOG 9413)

OriginalPaper

Phase II Study of Intravenous Doxil® in Malignant Pleural Mesothelioma

OriginalPaper

A Randomized Trial Comparing the Nephrotoxicity of Cisplatin/Ifosfamide-Based Combination Chemotherapy with or without Amifostine in Patients with Solid Tumors

OriginalPaper

Phase II Trial of Pyrazoloacridine as Second-Line Therapy for Patients with Unresectable or Metastatic Transitional Cell Carcinoma

OriginalPaper

Development of Multidrug-Resistance Convertors: Sense or Nonsense?

OriginalPaper

Phase II Trial of Liposomal Doxorubicin (Doxil®) in Advanced Soft Tissue Sarcomas
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits